open access

Vol 78, No 9 (2020)
Review paper
Published online: 2020-07-24
Get Citation

Statins plus ezetimibe in the era of proprotein convertase subtilisin/ kexin type 9 inhibitors

Leonardo De Luca, Alberto Corsini, Massimo Uguccioni, Furio Colivicchi
DOI: 10.33963/KP.15529
·
Pubmed: 32716152
·
Kardiol Pol 2020;78(9):850-860.

open access

Vol 78, No 9 (2020)
Review article
Published online: 2020-07-24

Abstract

Statins are first‑line agents used in patients with dyslipidemia, which show established benefits in reducing low‑density lipoprotein cholesterol (LDL‑C) levels and decreasing the rate of cardiovascular events. However, a considerable number of patients on statins do not achieve target LDL‑C levels, even at maximally tolerated statin doses, or are intolerant to intensive statin therapy. These patients can benefit from the addition of a nonstatin lipid‑lowering agent, and recent cholesterol guidelines have put greater focus on combination lipid‑lowering therapy. In patients who cannot achieve target treatment goals with statin therapy alone, the addition of a cholesterol absorption inhibitor, ezetimibe, leads to further LDL‑C reduction with good tolerability and decreases cardiovascular morbidity and mortality. The more recent proprotein convertase subtilisin‑like / kexin type 9 (PCSK‑9) inhibitors can lower LDL‑C by additional 45% to 65% and are also well tolerated. These complementary approaches for LDL‑C lowering in patients treated with statins decrease LDL‑C levels more effectively than statin monotherapy. As no threshold level has been established below which LDL‑C lowering benefits disappear, the early application of a combination treatment strategy may lead to improved cardiovascular outcomes, particularly in high‑risk patients. This review examines the rationale, advantages, and potential barriers to combination lipid‑lowering therapy with reference to the current guideline recommendations.

Abstract

Statins are first‑line agents used in patients with dyslipidemia, which show established benefits in reducing low‑density lipoprotein cholesterol (LDL‑C) levels and decreasing the rate of cardiovascular events. However, a considerable number of patients on statins do not achieve target LDL‑C levels, even at maximally tolerated statin doses, or are intolerant to intensive statin therapy. These patients can benefit from the addition of a nonstatin lipid‑lowering agent, and recent cholesterol guidelines have put greater focus on combination lipid‑lowering therapy. In patients who cannot achieve target treatment goals with statin therapy alone, the addition of a cholesterol absorption inhibitor, ezetimibe, leads to further LDL‑C reduction with good tolerability and decreases cardiovascular morbidity and mortality. The more recent proprotein convertase subtilisin‑like / kexin type 9 (PCSK‑9) inhibitors can lower LDL‑C by additional 45% to 65% and are also well tolerated. These complementary approaches for LDL‑C lowering in patients treated with statins decrease LDL‑C levels more effectively than statin monotherapy. As no threshold level has been established below which LDL‑C lowering benefits disappear, the early application of a combination treatment strategy may lead to improved cardiovascular outcomes, particularly in high‑risk patients. This review examines the rationale, advantages, and potential barriers to combination lipid‑lowering therapy with reference to the current guideline recommendations.

Get Citation
About this article
Title

Statins plus ezetimibe in the era of proprotein convertase subtilisin/ kexin type 9 inhibitors

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 78, No 9 (2020)

Article type

Review paper

Pages

850-860

Published online

2020-07-24

Page views

303

Article views/downloads

264

DOI

10.33963/KP.15529

Pubmed

32716152

Bibliographic record

Kardiol Pol 2020;78(9):850-860.

Authors

Leonardo De Luca
Alberto Corsini
Massimo Uguccioni
Furio Colivicchi

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Sp. z o.o. VM Group Sp.k., ul. Świętokrzyska 73 , 80–180 Gdańsk, Poland

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl